Quality of life in patients with liver tumors treated with holmium-166 radioembolization.
Adult
Aged
Aged, 80 and over
Embolization, Therapeutic
/ adverse effects
Fatigue
/ diagnosis
Female
Health Status
Holmium
/ adverse effects
Humans
Liver Neoplasms
/ radiotherapy
Male
Microspheres
Middle Aged
Pain
/ diagnosis
Palliative Care
/ methods
Quality of Life
Radioisotopes
/ adverse effects
Severity of Illness Index
Surveys and Questionnaires
Time Factors
Treatment Outcome
Hepatic metastases
Holmium-166
Quality of life
Radioembolization
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
14
08
2019
accepted:
09
11
2019
pubmed:
17
11
2019
medline:
22
9
2020
entrez:
17
11
2019
Statut:
ppublish
Résumé
Holmium-166 radioembolization is a palliative treatment option for patients with unresectable hepatic malignancies. Its influence on quality of life has not been evaluated yet. Since quality of life is very important in the final stages of disease, the aim of this study was to evaluate the effect of holmium-166 radioembolization on quality of life. Patients with hepatic malignancies were treated with holmium-166 radioembolization in the HEPAR I and II studies. The European Organization for Research and Treatment of Cancer QLQ-C30 and LMC21 questionnaires were used to evaluate quality of life at baseline, 1 week, 6 weeks and at 6, 9 and 12 months after treatment. The course of the global health status and symptom and functioning scales were analyzed using a linear mixed model. Quality of life was studied in a total of 53 patients with a compliance of 94%. Role functioning was the most affected functioning scale. Fatigue and pain were the most affected symptom scales. Changes in almost all categories were most notable at 1 week after treatment. A higher WHO performance score at baseline decreased global health status, physical functioning, role functioning and social functioning and it increased symptoms of fatigue, dyspnea and diarrhea. Quality of life in salvage patients with liver metastases treated with holmium-166 radioembolization was not significantly affected over time, although a striking decline was seen during the first week post-treatment. A WHO performance score > 0 at baseline significantly influenced quality of life.
Identifiants
pubmed: 31732841
doi: 10.1007/s10585-019-10006-1
pii: 10.1007/s10585-019-10006-1
pmc: PMC7007912
doi:
Substances chimiques
Holmium-166
0
Radioisotopes
0
Holmium
W1XX32SQN1
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-105Références
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33
pubmed: 11858978
Cancer Treat Rev. 2016 Nov;50:148-154
pubmed: 27690234
R Soc Open Sci. 2014 Nov 19;1(3):140216
pubmed: 26064558
Lancet Oncol. 2017 Sep;18(9):1159-1171
pubmed: 28781171
J Nucl Med. 2013 Dec;54(12):2093-100
pubmed: 24136931
Front Oncol. 2014 Jul 29;4:198
pubmed: 25120955
BMC Cancer. 2018 Jan 12;18(1):75
pubmed: 29329568
Ann Oncol. 2001 Dec;12(12):1711-20
pubmed: 11843249
Lancet Oncol. 2012 Oct;13(10):1025-34
pubmed: 22920685
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Abdom Radiol (NY). 2019 Apr;44(4):1554-1561
pubmed: 30311050
J Geriatr Oncol. 2013 Jan;4(1):71-7
pubmed: 24071494
JAMA Oncol. 2015 Sep;1(6):778-84
pubmed: 26203912
Cancer. 2008 Dec 15;113(12):3459-66
pubmed: 18988231
J Palliat Med. 2015 Feb;18(2):176-86
pubmed: 25259624
J Nucl Med. 2018 Apr;59(4):582-588
pubmed: 28916623
Digestion. 2009;79(3):137-42
pubmed: 19307736
Dis Colon Rectum. 2019 Nov;62(11):1294-1304
pubmed: 31567919
World J Radiol. 2016 May 28;8(5):449-59
pubmed: 27247711
Oncol Res Treat. 2014;37(9):472-8
pubmed: 25231687
J Exp Clin Cancer Res. 2010 Jun 15;29:70
pubmed: 20550679
Clin Nucl Med. 2016 Dec;41(12):e493-e497
pubmed: 27749405
Psychooncology. 2004 Feb;13(2):73-9
pubmed: 14872525
J Surg Oncol. 2004 Nov 1;88(2):78-85
pubmed: 15499601
J Surg Res. 2020 Jan;245:257-264
pubmed: 31421371
Liver Int. 2015 Jun;35(6):1715-21
pubmed: 25443863
PLoS One. 2016 Dec 8;11(12):e0167967
pubmed: 27930703
Br J Cancer. 2010 Jul 27;103(3):324-31
pubmed: 20628388
J Clin Oncol. 2003 Jul 1;21(13):2589-96
pubmed: 12829680
PLoS One. 2014 Mar 10;9(3):e90909
pubmed: 24614178
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1358-1365.e1
pubmed: 23644386
Br J Surg. 2009 Mar;96(3):291-8
pubmed: 19224519
Future Oncol. 2018 Jul;14(17):1701-1710
pubmed: 29543521
J Nucl Med. 2015 Jul;56(7):1079-87
pubmed: 25952741
Afr Health Sci. 2011 Jun;11(2):266-70
pubmed: 21857860